Status:
TERMINATED
Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.
Lead Sponsor:
Pfizer
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.
Eligibility Criteria
Inclusion
- Patients with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease
- Patients must have a smoking history of at least 10 pack-years
- Patients must have stable disease for at least 1 month prior to screening.
Exclusion
- More than 2 exacerbations of COPD in the preceding year
- History of a lower respiratory tract infection or significant disease instability during the month proceding screening or during the time between screen and randomization.
- History or presence of respiratory failure, cor pulmonale or right ventricular failure
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00430300
Start Date
January 1 2007
End Date
July 1 2008
Last Update
July 8 2013
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Camperdown, New South Wales, Australia, 2050
2
Pfizer Investigational Site
Glebe, New South Wales, Australia, 2037
3
Pfizer Investigational Site
Daw Park, South Australia, Australia, 5041
4
Pfizer Investigational Site
Nedlands, Western Australia, Australia, 6009